Related Experiment Videos
Modulation of tumor growth by crossreacting isoantibodies
P Nguyen Van Binh1, Y S Lone, H Thien Duc
1Inserm U268, InstitutAndré-Lwoff Hĵpital Paul-Brousse, Villejuif, France.
Abstract:
Tumor cells transfected with strong antigenic epitopes were able to stimulate humoral response against relevant wild-type tumors. Crossreacting immune sera have been obtained by immunizing C57BL/6 mice with OVA-transfected leukemia EL-4 (subclone E.G7) and OVA-transfected melanoma B16 (subclone MO.5) stimulated with interferon-gamma. Tumors were significantly inhibited when antisera were injected subcutaneously close to the site of solid wild-type tumors EL-4 and B16 grafted onto C57BL/6 mice.
Insights
Tumor cells engineered with antigenic epitopes can trigger an immune response, leading to the inhibition of wild-type tumors in mice. This study demonstrates a novel approach for cancer immunotherapy using cross-reacting immune sera.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Tumor cells can be engineered to express foreign antigens, potentially stimulating an immune response against cancer.
- Interferon-gamma stimulation can enhance antigen presentation and immune cell activity.
Purpose of the Study:
- To investigate the potential of using immune sera generated against transfected tumor cells to inhibit wild-type tumor growth.
- To evaluate the efficacy of cross-reacting antibodies in a preclinical cancer model.
Main Methods:
- C57BL/6 mice were immunized with ovalbumin (OVA)-transfected leukemia EL-4 and melanoma B16 cells, stimulated with interferon-gamma.
- Immune sera were collected and injected subcutaneously near solid wild-type EL-4 and B16 tumors grafted onto mice.
Main Results:
- Immunization with OVA-transfected tumor cells successfully generated cross-reacting immune sera.
- Subcutaneous injection of these antisera significantly inhibited the growth of wild-type EL-4 and B16 tumors.
Conclusions:
- Engineered tumor cells expressing strong antigenic epitopes can elicit a humoral immune response capable of targeting and inhibiting wild-type tumors.
- This approach shows promise as a potential cancer immunotherapy strategy.